logo
  • Home
  • About Us
  • Cognition
  • Pipeline
  • News
  • Talent
  • Contact
中
  • Industry Trends
  • Technological Frontier
  • Information of YuanVore
Location: Home > News > Industry Trends
  • The clinical trial of iPS cell therapy for Parkinson's disease at Xuanwu Hospital, Capital Medical University, has been initiated
    01
    2025-09
    2025-09-01
    With the acceleration of global population aging, Parkinson's disease has become the second most common neurodegenerative disorder after Alzheimer's disease, affecting the health and quality of life of over ten million people worldwide.
  • Nine cell and gene therapies have been launched in China, and the research and development vitality of CGT continues to lead the world
    29
    2025-08
    2025-08-29
    In recent years, Cell & Gene Therapy (CGT) has been creating a strong wave worldwide.
  • The most crucial link in the field of biopharmaceuticals: CMC
    27
    2025-08
    2025-08-27
    CMC (Chemistry, Manufacturing and Control) plays a crucial role in the field of biopharmaceuticals, ensuring a smooth transition of biopharmaceuticals from the laboratory to the commercialization stage.
  • Nine cell and gene therapy drugs have been launched on the market: one each for stem cells and genes, and seven for CAR-T
    25
    2025-08
    2025-08-25
    Up to now, nine CGT drugs have been officially launched on the market, covering the three core technologies of CAR-T, stem cells and gene therapy.
  • New stem cell drugs are booming! The IND acceptance has exceeded 30+, and iPSC has ushered in a new era of cell therapy
    14
    2025-08
    2025-08-14
    According to incomplete statistics, the number of IND applications for new stem cell drugs in China has exceeded 30 in the first half of this year, showing a significant growth trend compared to the 39 applications for the whole of 2024.
  • The world's first iPS cell therapy has been submitted for marketing: Parkinson's disease is expected to move from "symptomatic treatment" to the "neuron repair" era
    11
    2025-08
    2025-08-11
    Recently, Sumitomo Pharma of Japan and Racthera jointly announced that they have submitted an application for the production and marketing authorization of raguneprocel to the regulatory authorities.
  • The new stem cell drug in Phase 3 clinical trials in China is expected to be launched as early as 2026
    04
    2025-08
    2025-08-04
    At present, six stem cell therapy projects in China are in the critical Phase III clinical trial stage, which indicates that the field of stem cell drugs is experiencing an important turning point.
  • China's iPS cell therapy has raised more funds than T cells for the first time, opening a new chapter in regenerative medicine
    29
    2025-07
    2025-07-29
    In the first half of 2025, a major piece of news emerged in China's regenerative medicine field: the total financing amount of iPSC (induced pluripotent stem cells, iPS cells) therapy companies surpassed that of T-cell therapy companies for the first time.
Prev
1 2 3 ...
Next
logo

Phone:021-64051958

Email:info@yuanvore.com

  • Cognition
    Cognition
    CellBank
    Platform
    Patent
  • Pipeline
    PipelineLayout
  • News
    Industry Trends
    Technological Frontier
    Information of YuanVore
  • Talent
    Enterprise Culture
    Job Information
  • About Us
    Contact Us
CopyRight @ 2023 Shanghai Yuanvore Medicine Technology Co., Ltd. AIl Rights Reserved 沪ICP备2023021701号

沪公网安备31011202020042号